AQST vs JNJ: fair value comparison
Aquestive Therapeutics, Inc. and Johnson & Johnson · Updated 2026-10-19
AQST has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, JNJ currently ranks higher by quality score.
| AQST | JNJ | |
|---|---|---|
| Verdict | No estimate yet | Overvalued |
| Last price | $3.78 | $261.44 |
| 12-month range | $2.95–$7.01 | $186.00–$278.43 |
| Rank by discount to fair value | — | #87 of 108 Healthcare |
| Rank by quality score | #150 of 301 Healthcare | #149 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: AQST fair value analysis · JNJ fair value analysis